Cargando…
Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain
Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice,...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017507/ https://www.ncbi.nlm.nih.gov/pubmed/33850929 http://dx.doi.org/10.12998/wjcc.v9.i9.2100 |
_version_ | 1783674069075361792 |
---|---|
author | Xiao, Hong Ma, Ke Huang, Dong Liu, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Song, Tao Tao, Wei Wu, Da-Sheng Wang, Yun-Xia Yang, Xiao-Qiu Zhang, Xiao-Mei Liu, Hui Liu, Yan-Qing |
author_facet | Xiao, Hong Ma, Ke Huang, Dong Liu, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Song, Tao Tao, Wei Wu, Da-Sheng Wang, Yun-Xia Yang, Xiao-Qiu Zhang, Xiao-Mei Liu, Hui Liu, Yan-Qing |
author_sort | Xiao, Hong |
collection | PubMed |
description | Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP. |
format | Online Article Text |
id | pubmed-8017507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-80175072021-04-12 Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain Xiao, Hong Ma, Ke Huang, Dong Liu, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Song, Tao Tao, Wei Wu, Da-Sheng Wang, Yun-Xia Yang, Xiao-Qiu Zhang, Xiao-Mei Liu, Hui Liu, Yan-Qing World J Clin Cases Expert Consensus Neuropathic pain (NPP) is a kind of pain caused by disease or damage impacting the somatosensory system. Ion channel drugs are the main treatment for NPP; however, their irregular usage leads to unsatisfactory pain relief. To regulate the treatment of NPP with ion channel drugs in clinical practice, the Chinese Association for the Study of Pain organized first-line pain management experts from China to write an expert consensus as the reference for the use of ion channels drugs . Here, we reviewed the mechanism and characteristics of sodium and calcium channel drugs, and developed recommendations for the therapeutic principles and clinical practice for carbamazepine, oxcarbazepine, lidocaine, bulleyaconitine A, pregabalin, and gabapentin. We hope this guideline provides guidance to clinicians and patients on the use of ion channel drugs for the management of NPP. Baishideng Publishing Group Inc 2021-03-26 2021-03-26 /pmc/articles/PMC8017507/ /pubmed/33850929 http://dx.doi.org/10.12998/wjcc.v9.i9.2100 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Expert Consensus Xiao, Hong Ma, Ke Huang, Dong Liu, Xian-Guo Liu, Tang-Hua Liu, Qing Liu, Guang-Zhao Song, Tao Tao, Wei Wu, Da-Sheng Wang, Yun-Xia Yang, Xiao-Qiu Zhang, Xiao-Mei Liu, Hui Liu, Yan-Qing Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title | Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title_full | Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title_fullStr | Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title_full_unstemmed | Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title_short | Expert consensus of the Chinese Association for the Study of Pain on ion channel drugs for neuropathic pain |
title_sort | expert consensus of the chinese association for the study of pain on ion channel drugs for neuropathic pain |
topic | Expert Consensus |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017507/ https://www.ncbi.nlm.nih.gov/pubmed/33850929 http://dx.doi.org/10.12998/wjcc.v9.i9.2100 |
work_keys_str_mv | AT xiaohong expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT make expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT huangdong expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liuxianguo expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liutanghua expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liuqing expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liuguangzhao expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT songtao expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT taowei expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT wudasheng expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT wangyunxia expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT yangxiaoqiu expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT zhangxiaomei expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liuhui expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain AT liuyanqing expertconsensusofthechineseassociationforthestudyofpainonionchanneldrugsforneuropathicpain |